FRANKFURT (Reuters) - German drugmaker Merck KGaA said it struck a deal with Lupin Limited to market some of the Indian drugmaker's cardiovascular and diabetes treatments in emerging markets.
The partnership covers Brazil, Mexico, Indonesia, Philippines as well as several countries in Africa and eastern Europe, among others, Merck said in a statement on Tuesday.
The deal could add up to 20 new drugs to Merck's current portfolio and first product launches are expected in 2016, it added.
Last year, emerging markets accounted for close to 1.8 billion euros ($2.3 billion) of total sales of 6 billion euros at Merck's prescription drugs unit Merck Serono.
Lupin and Merck agreed not to disclose financial terms.
(Reporting by Ludwig Burger; Editing by Harro ten Wolde)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app